Use of Acellular Dermal Matrix Following Fasciectomy for the Treatment of Dupuytren’s Disease

Background: Recurrence rates following surgical intervention for Dupuytren’s disease (DD) remain high. In this study, we investigate the use of acellular dermal matrix (ADM) to reduce recurrence and improve long-term clinical outcome.

Methods: We examined 132 patients undergoing open fasciectomy for DD from 2007 to 2017. The experimental group had a sheet of ADM (FlexHD) sutured into the surgical bed controls were not closed with ADM. Patient characteristics, range of motion, and complications were examined.

Results: Twenty-eight (21.2%) patients were treated with acellular dermal matrix, whereas 104 (78.8%) patients were not. The median age was 67.0 years (range 34–91 years), with no differences between group regarding age, comorbidities, and laterality. The mean preoperative interphalangeal joint flexion contracture in the ADM group of 66.5 ± 29.9 degrees was corrected to 9.7 ± 12.4 degrees, whereas the mean metacarpophalangeal joint preoperative flexion contracture of 51.4 ± 23.9 degrees was corrected to 7.8 ± 14.1 degrees at postoperative examination (P < 0.05). The median follow-up was 18.7 months, during which the recurrence of contracture was observed in 1 of 28 patients in the group receiving ADM compared with 9 of 104 in the control group (P = 0.37). There were no differences in the incidence of minor wound complications observed.

Conclusion: The adjunct placement of acellular dermal matrix into the wound bed following fasciectomy for DD may be an important surgical strategy to reduce recurrence rates as well as augment coverage of exposed vital structures in cases of severe flexion contracture. (Plast Reconstr Surg Glob Open 2019;7:e2263; doi: 10.1097/GOX.0000000000002263; Published online 28 May 2019.)

INTRODUCTION

An inheritable disorder of autosomal dominance, Dupuytren’s disease (DD) is a common fibroproliferative disorder causing flexion contractures of the hand. It is known to affect individuals between the fifth and seventh decades, with a geographical distribution that broadly follows the migration patterns of Northern Europeans around the globe. Most commonly DD involves contracture of the small finger, with a single digit involved in 60% of the patients. The tissue in DD is composed of cords, consisting of scanty fibroblasts, and nodules, consisting of whorls of cells. The contractile ability of the disease is the result of myofibroblasts’ cells that are otherwise typically seen in normal wound healing. In DD, the formation of nodules and cords progresses from an initial cellular proliferative stage, through an intermediate fibrocellular stage, to a terminal fibrotic stage.

A contracture that interferes with function is the most common indication for surgical intervention. Various surgical treatment modalities exist, such as fasciectomy, fasciectomy, and dermofasciectomy. However, recurrence rates remain high following surgical treatment, which ranges from 12% to 39%. In 1979, Rudolph demonstrated that myofibroblasts are inhibited by the presence of full-thickness skin grafts, and in 1993, McCann et al observed that in a large proportion of samples from patients with DD, myofibroblasts were found to be extending into the dermis. These findings may demonstrate why procedures

Disclosure: The authors have no financial interest to declare in relation to the content of this article.
that leave the overlying dermis intact have a high recurrence rate, possibly due to the abnormal interaction between the overlying dermis and underlying connective tissue layers in the development of DD. Previous studies demonstrate recurrence rates as low as 12.2% with use of a full-thickness skin graft and <5% with use of acellular dermal matrix (ADM) as reported by a single study. In this study, we aimed to further evaluate the use of ADM to reduce recurrence rates based on the postulate that ADM has an inhibitory effect on underlying myofibroblasts.

**METHODS**

We performed a retrospective cohort study of 132 patients undergoing open fasciectomy for DD from years 2007 to 2017 performed by a single surgeon (DK) at our academic institution. Only patients with symptomatic DD with the presence of nodules and/or joint contracture were included in this study.

Standard McCash technique fasciectomies of affected palmar and digital fascia were performed. Patients in the experimental group had a sheet of ADM (FlexHD; Musculoskeletal Transplant Foundation, Edison, NJ) sutured into the surgical bed with absorbable sutures (Fig. 1), whereas patients in the control group were not closed with ADM. ADM was utilized in place of a full-thickness skin graft. The thickness of the ADM was not measured in each patient, but product specifications were followed from manufacturer (Table 1). Patients in the control group were not closed with acellular dermal matrix but instead were allowed to heal by secondary intention. Patients were then evaluated at follow-up for disease recurrence, defined as the presence of Dupuytren tissue in an area previously operated on with a contracture greater than that recorded following the surgical fasciectomy, or presence of contracture requiring surgery.

**RESULTS**

Results are detailed in Table 2. Among the cohort of 132 patients, 28 (21.2%) patients were treated with acellular dermal matrix (Figs. 2, 3), whereas 104 (78.8%) patients were not. The median age was 67.0 years (range 34–91 and 39–82 years in the control and dermal matrix groups, respectively). No statistical difference existed between each group regarding age, comorbidities, and laterality. The most common comorbidity was a smoking history, with 34% in the control group versus 43% in the dermal matrix group.

**Table 1. Structure and Dimension of ADM**

| Tissue Code | FlexHD Structural Thin |
|-------------|------------------------|
| 470102      | FlexHD structural, thin: 1 cm (W) × 2 cm (L) × 0.4–0.8 mm thick |
| 470204      | FlexHD structural, thin: 2 cm (W) × 4 cm (L) × 0.4–0.8 mm thick |
| 470307      | FlexHD structural, thin: 3 cm (W) × 7 cm (L) × 0.4–0.8 mm thick |
| 470407      | FlexHD structural, thin: 4 cm (W) × 7 cm (L) × 0.4–0.8 mm thick |

**Statistical Analyses**

Bivariate analysis was performed using the chi-square test. Wilcoxon signed rank test and Mann–Whitney test were used to determine statistical differences between the paired pre- and postoperative measurements. P values were two-tailed, and values ≤0.05 were defined as statistically significant.
corrected to 9.7±12.4 degrees, whereas the mean metacarpophalangeal joint preoperative flexion contracture of 51.4±23.9 degrees was corrected to 7.8±14.1 degrees at postoperative examination (P < 0.05). The median follow-up was 18.7 months, during which the recurrence of contracture was observed in 1 of 28 patients in the group receiving ADM, compared with 9 of 104 in the control group (P = 0.37). Of all patients, 2 complications occurred in the control group—infection and complex regional pain syndrome. There were no differences in the incidence of complications observed.

**DISCUSSION**

Ongoing debate exists regarding the optimal surgical method in treating DD—whether to utilize traditional open fasciectomy, limited procedures, or less invasive techniques, as well as when to use alternative operative techniques such as wide-awake open release and 2-stage treatments. Reported recurrence rates for open fasciectomy in treating DD varies widely within current literature. Multiple large studies with long-term follow-up suggest that these traditional procedures are associated with high recurrence rates, from 39% following fasciectomy to 62% following fascioplasty. Hueston reported in 1962 and 1969 the observation of no recurrences in patients who underwent full-thickness excision of skin and diseased fascia and full-thickness skin grafting, later termed dermofasciectomy. Since then, additional studies demonstrate the lower recurrence rates for dermofasciectomy, further suggesting the association of the dermis overlying the diseased fascia with disease recurrence. Therefore, it has been hypothesized that a barrier between the wound bed and the overlying dermis could replicate the success rate of dermofasciectomy by blocking the interaction between wound and dermis and thus avoid the disadvantages in excising the skin completely and using full-thickness skin grafts.

Human ADM was released in 1994 for the replacement of inadequate integumental tissue due to burn injury and has since been found useful as skin replacement for its ability to retain elastin and collagen fibers after undergoing de-cellularization and sterilization. In a review on the use of ADM in forearm, wrist, and hand reconstruction, Ellis and Kulber found that ADM offers innovative utility in solving upper extremity surgical problems, but that more comparative trials are necessary. Nevertheless, little is known about the use of ADM in surgically treating DD and has only previously been studied in small cohorts and implicated as a successful viable alternative to the standard procedure. In this study, we observed similar results to that of Terry et al. Although not statistically significant, there was a trend toward lower recurrence rates in the ADM group. The patient history, such as experience with age, laterality, previous surgery, and comorbidities, was similar regardless of treatment group. Interestingly, flexion of the MPJ was significantly better both preoperatively and postoperatively in the dermal matrix group and complication rates were comparable and low to none for both groups. This indicates that ADM is a viable surgical option, but further studies are required, with a larger sample size, to elucidate this option.

| Characteristic                      | Control Group (n = 104) | Dermal Matrix Group (n = 28) | P      |
|------------------------------------|-------------------------|-----------------------------|--------|
| Median age (y)                     | 67.00                   | 67.00                       | 1.000  |
| Minimum–maximum (y)                | 34–91                   | 39–82                       | 0.300  |
| Laterality                         | Left: 51                | 10                          |        |
|                                    | Right: 51               | 17                          |        |
|                                    | Bilateral: 1            | 1                           |        |
| Previous treatment                 | 46                      | 16                          | 0.287  |
| Collagenase                        | 10                      | 4                           |        |
| Surgery                            | 36                      | 12                          |        |
| Comorbidities                      | Diabetes: 15            | 3                           | 0.763  |
|                                    | Prostate cancer: 4      | 1                           | 1.000  |
|                                    | Beta blocker use: 17    | 1                           | 0.119  |
|                                    | Significant alcohol history: 9 | 6                           | 0.088  |
|                                    | Smoking history: 35     | 12                          | 0.382  |
|                                    | History of seizure disorder: 2 | 0                           | 1.000  |
| Distribution of affected area      | Palm: 101               | 28                          | 1.000  |
|                                    | Thumb: 11               | 5                           | 0.330  |
|                                    | IF: 15                  | 9                           | 0.050  |
|                                    | MF: 56                  | 17                          | 0.298  |
|                                    | RF: 72                  | 23                          | 0.238  |
|                                    | SF: 67                  | 26                          | 0.002  |
| Flexion IPJ contracture (degrees)  | Preoperative mean: 50.5 | 66.5                        | 0.007  |
|                                    | Postoperative mean: 2.1  | 9.7                         | 0.002  |
|                                    | Mean improvement: 48.4  | 56.8                        | 0.194  |
| Flexion MPJ contracture (degrees)  | Preoperative mean: 41.7 | 51.4                        | 0.069  |
|                                    | Postoperative mean: 0.5  | 7.8                         | 0.018  |
|                                    | Mean improvement: 41.3  | 43.6                        | 0.617  |
| Median follow-up (mo)              | Minimum–maximum (mo): 52.06 | 18.73                      | 0.001  |
|                                    | Recurrence: 9 (9%)      | 1 (4%)                      | 0.368  |
| Complications                      | Infection: 1            | 0                           |        |
|                                    | Hematoma: 0             | 0                           |        |
|                                    | CRPS: 1                 | 0                           |        |
|                                    | Nerve injury: 0         | 0                           |        |
|                                    | Devascularized digit: 0 | 0                           |        |
|                                    | Skin necrosis: 0        | 0                           |        |
| IF, MF, RF, SF, IF, index finger; MF, middle finger; RF, ring finger; SF, small finger; CRPS, complex regional pain syndrome; IPJ, interphalangeal joint; MPJ, metacarpophalangeal joint.

As such, our study is not without limitations, with an unequal distribution of patients between the experimental and control groups. Furthermore, the experimental ADM group had shorter follow-up and fewer patients than the control group. However, we hope that these results can lead to a prospective double-blinded study that can further elucidate surgical treatment utilizing ADM for DD. An ideal future study can involve a prospective study of greater power with similar duration, longer follow-up, and an additional control group with skin grafting.

Overall, we found that the adjunct placement of acellular dermal matrix into the wound bed following fasciectomy for DD may be an important surgical strategy to reduce recurrence rates as well as augment coverage of exposed vital structures in cases of severe flexion contracture.
Fig. 2. Closure with ADM of palm and fifth digit. (A) Preoperative and (B) postoperative views of palm and fifth digit closed with ADM.

Fig. 3. Postoperative view of patient showing improved range of motion (ROM).

REFERENCES

1. Birks M, Bhalla A. Dupuytren’s disease. Surgery. 2013;31:177–e180.
2. Dias J, Braybrooke J. Dupuytren’s contracture: an audit of the outcomes of surgery. J Hand Surg Br. 2006;31:514–521.
3. Balaguè T, David S, Ibrai T, et al. Histological staging and Dupuytren’s disease recurrence or extension after surgical treatment: a retrospective study of 124 patients. J Hand Surg Eur Vol. 2009;34:493–496.
4. Rudolph R. Inhibition of myofibroblasts by skin grafts. Plast Reconstr Surg. 1979;63:473–480.
5. McCann BG, Logan A, Belcher H, et al. The presence of myofibroblasts in the dermis of patients with Dupuytren’s contracture: A possible source for recurrence. *J Hand Surg Br.* 1993;18: 656–661.

6. Terry MJ, Sue GR, Goldberg C, et al. Hueston revisited: use of acellular dermal matrix following fasciectomy for the treatment of Dupuytren’s disease. *Ann Plast Surg.* 2014;73(suppl 2):S178–S180.

7. Ullah AS, Dias JJ, Bhowal B. Does a ‘firebreak’ full-thickness skin graft prevent recurrence after surgery for Dupuytren’s contracture?: a prospective, randomised trial. *J Bone Joint Surg Br.* 2009;91:374–378.

8. Sweet S, Blackmore S. Surgical and therapy update on the management of Dupuytren’s disease. *J Hand Ther.* 2014;27:77–83; quiz 84.

9. Crean SM, Gerber RA, Le Graverand MP, et al. The efficacy and safety of fasciectomy and fasciotomy for Dupuytren’s contracture in European patients: a structured review of published studies. *J Hand Surg Eur Vol.* 2011;36:396–407.

10. Hueston JT. Digital Wolfe grafts in recurrent Dupuytren’s contracture. *Plast Reconstr Surg Transplant Bull.* 1962;29:342–344.

11. Hueston JT. The control of recurrent Dupuytren’s contracture by skin replacement. *Br J Plast Surg.* 1969;22:159–156.

12. Abe Y, Rokkaku T, Kaniyoshi K, et al. Clinical results of dermofasciectomy for Dupuytren’s disease in Japanese patients. *J Hand Surg Eur Vol.* 2007;32: 407–410.

13. Armstrong JR, Hurren JS, Logan AM. Dermofasciectomy in the management of Dupuytren’s disease. *J Bone Joint Surg Br.* 2000;82:99–94.

14. Brotherston TM, Balakrishnan C, Milner RH, et al. Long term follow-up of dermofasciectomy for Dupuytren’s contracture. *Br J Plast Surg.* 1994;47:440–443.

15. Hall PN, Fitzgerald A, Sterne GD, et al. Skin replacement in Dupuytren’s disease. *J Hand Surg Br.* 1997;22:193–197.

16. Kelly SA, Burke FD, Elliot D. Injury to the distal radius as a trigger to the onset of Dupuytren’s disease. *J Hand Surg Br.* 1992;17: 225–229.

17. Logan AM, Brown HG, Lewis-Smith P. Radical digital dermofasciectomy in Dupuytren’s disease. *J Hand Surg Br.* 1985;10:353–357.

18. Ketchum LD, Hixson FP. Dermofasciectomy and full-thickness grafts in the treatment of Dupuytren’s contracture. *J Hand Surg Am.* 1987;12(5 pt 1):659–664.

19. Tonkin MA, Burke FD, Varian JP. Dupuytren’s contracture: a comparative study of fasciectomy and dermofasciectomy in one hundred patients. *J Hand Surg Br.* 1984;9:156–162.

20. Searle AE, Logan AM. A mid-term review of the results of fasciectomy for Dupuytren’s disease. *Ann Chir Main Memb Super.* 1999;1:375–380.

21. Musculoskeletal Transplant Foundation and Ethicon. FlexHD (brochure); 2010.

22. Ellis CV, Kulber DA. Acellular dermal matrices in hand reconstruction. *Plast Reconstr Surg.* 2012;130(5 suppl 2):256S–269S.